Cancer Care

 

 
 
STEAM (Sequencing Triplet with Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
Principal Investigator (?)
Study Number
F13044
Summary
This randomized, open-label, multicenter study will evaluate the efficacy and safety of FOLFOXIRI/Avastin (bevacizumab) regimens (concurrent and sequential) versus FOLFOX/Avastin in first-line in patients with metastatic colorectal cancer. Patients will be randomized to receive Avastin 5 mg/kg intravenously every 2 weeks with either concurrent or sequential FOLFOXIRI or with FOLFOX for 4 to 6 months of induction therapy, followed by maintenance therapy with Avastin plus either leucovorin/5-fluorouracil or capecitabine until disease progression occurs. After disease progression, patients will receive treatment with a fluoropyrimidine-based chemotherapy plus Avastin. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Manchester

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.